

F. No. IND/CT/21/000018

Tele No.011-23236965
Fax.No.011-23236973

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

To

M/s Natco Pharma Limited,
Natco Pharma Limited, Natco House Road No-2,
Banjara Hills Hyderabad (India)-500034.

18 MAY 2021

Subject:- Permission for conducting clinical study entitled, "A prospective, randomized, parallel, multicentric, phase-III clinical trial of Molnupiravir 800 mg capsules and standard of care (SOC) compared to standard of care only in confirmed RT-PCR positive patients with mild COVID-19" Protocol CBCC/2021/008, Version Number 4.0, dated 11.05.2021- regarding.

Sir,

With reference to your Application No. IND/CT04/FF/2021/25180 dated 23.04.2021, please find enclosed herewith the permission in **Form CT-06, No. CT/ND/49/2021** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trial Rules, 2019** granted based on evaluation in consultation with Subject Expert Committee (SEC) as part of accelerated approval process in light of COVID 19 outbreak.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

(Dr. V. G. Somani)
Central Licensing Authority

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

Condition of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7;

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of

- receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) **RTPCR test should be done at 5, 10 and 15 days of the study.**
- (xx) **Patients aged limit should be 18 to 60 years.**
- (xxi) **Sample size should be atleast 1218 mild COVID patients in randomized 1:1 ratio into Test: Reference arm.**

FORM CT-06*(See rules 22, 25, 26, 29 and 30)***PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL
NEW DRUG**

The Central Licensing Authority hereby M/s Natco Pharma Limited, Natco Pharma Limited, Natco House Road No-2, Banjara Hills Hyderabad (India)-500034 to conduct clinical trial of the investigational new drug as per CBCC/2021/008, Version Number 4.0, dated 11.05.2021 in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:		Molnupiravir Capsules 200mg		
Therapeutic class:		Antiviral		
Dosage form:		Capsules		
Composition:		Each capsule contains.....Molnupiravir 200mg		
Indications:		COVID-19		
Details of clinical trial sites-				
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Registration Number	Committee	Name/
01	Dr. Chirag Rathod MD Medicine, GMERS Medical College & Hospital, Gotri, Vadodara-390021, Gujarat, India	Institutional Committee,	Human	Ethics
02	Dr. Swapnil Suresh Sakhala Consultant Pulmonologist, Chopda Medicare & Research Centre Pvt. Ltd, Magnum Heart Institute, 3/5, Patil Lane No.1, Laxmi Nagar, Near K.B.H, Vidyalaya, Canada Corner, Nashik-422005, Maharashtra, India	ECR/28/Inst/GJ-2013/RR-19 Magna-care Ethics Committee, ECR/79/Inst/MH/2013/RR-19		
03	Dr. Venkata Nagarjuna M Consultant – Pulmonology, Yashoda hospitals, Rajbhavan Road, Somajiguda, Matha Nagar, Hyderabad, Telangana	Institutional Ethics Committee, ECR/49/Inst/AP/2013/RR-16		
04	Dr. R S Raman, Senior Consultant, Maharaja Agrasen Hospital West Punjabi Bagh, New Delhi-110026	Institutional Ethics Committee ,Room No. 614,6th Floor, Maharaja Agrasen Hospital ,West Punjabi Bagh, New Delhi-110026,		

		ECR/745/Inst/DL/2015/RR-18
05	Dr. Archana Bhat Associate Professor, Father Muller Medical College Hospital Father Muller Road, Kankanady, Mangalore, Karnataka-575002.	Father Muller Institutional Ethics Committee, ECR/540/Inst/KA/2014/RR-20
06	Dr. Sanjay Kumar Kochar MD Medicine, Department of Medicine, S P Medical College & AG Hospitals, Bikaner- 334003, Rajasthan, India.	Ethics Committee, S.P Medical College, Bikaner, ECR/27/SP/Inst/RJ/2013/RR-19
07	Dr. Md. Sabah Siddique, MD Medicine, All India Institute of Medical Science, Raipur Tatibandh, GE Road, Raipur, Chhattisgarh-492099, -India	Institute Ethics Committee, AIIMS Raipur, ECR/714/inst/CT/2015/RR-21
08	Dr. Sharad Agarkhedkar Professor & Head of Department, Department of Pediatrics, Dr. D. Y. Patil Medical College, Hospital, Sant Tukaram Nagar, Pimpri Colony, Pimpri-Chinchwad, Maharashtra Pune 411018, India.	Ethics committee- Dr. D. Y. Patil Vidyapeeth, Pune, ECR/361/Inst/MH/2013/RR-19
9	Dr. Rajesh V Gosavi, Associate Professor, Government medical college & Hospital, Medical square road, Nagpur- 440003, Maharashtra, India.	Institution Ethics Committee, GMC, Nagpur, ECR/43/Inst/MH/2013/RR-19
10	Dr. Micky Shaileshbhai Patel General Physician, Department of General Medicine Lotus Multispecialty Hospital Block N Krupa Residency Motera Stadium Road Ahmedabad-380005, Gujarat, India.	Lotus Ethics Committee, ECR/990/Inst/GJ/2017/RR-20
11	Dr. C R Jayanthi General Physician, Victoria Hospital, Bangalore Medical College and Research Institute, Bangalore-02, Karnataka 560002, India	Ethics Committee of Bangalore Medical College and Research Institute, ECR/302/Inst/KA/2013/RR-20
12	Dr. Ravindra L. Kulkarni General Physician, Ashwin Medical Foundation's Mourya Multispecialty Hospital, Opposite PMP Bus stop, Power House Chowk, Chinchwadgaon, Pune, 411033-India	Moraya Institutional Ethics committee, ECR/657/inst/MH/2014/RR-20
13	Dr. Prakash Kurmi, General Physician, Shivam Hospital, Bopal - Ghuma main Road, above Bank of Baroda, Near Umiya Mata Temple, Purushottam Nagar, Circle, Bopal, Ahmedabad, Gujarat 380058, India.	Shivam Ethics Committee, ECR/63/Inst/GJ/2013/RR-20
14	Dr. Sameer Agarwal-Consultant Medicine, Tulasi Hospital India Limited, 14/116-A, Civil lines, Kanpur-208-001, India	Tulsi Hospital Ethics Committee, ECR/1401/Inst/UP/2020
15	Dr. Sudhir Prasad Consultant Pulmonology, Aware Gleneagles Global Hospitals, Suroornagar, Hyderabad, Telangana India	Institutional Ethics Committee Gleneagles Global Hospitals,

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.



(Dr. V. G. Somani)
Central Licensing Authority

Dr. V. G. SOMAN Stamp
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi

Date: ...18 MAY 2021